PHN — Pharmanutra SpA Income Statement
0.000.00%
Last trade - 00:00
- €498.06m
- €500.95m
- €100.20m
- 93
- 13
- 52
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 53.6 | 56.4 | 68.1 | 82.7 | 100 |
Cost of Revenue | |||||
Gross Profit | 50.8 | 53.7 | 65.8 | 79.9 | 97.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 41.4 | 43.2 | 49.4 | 59.7 | 76.8 |
Operating Profit | 12.2 | 13.2 | 18.7 | 23 | 23.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 12.2 | 13.3 | 18.8 | 23.4 | 23.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 8.45 | 14.1 | 13.8 | 15 | 12.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 8.45 | 14.1 | 13.8 | 15 | 12.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 8.45 | 14.1 | 13.8 | 15 | 12.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.873 | 1.5 | 1.44 | 1.56 | 1.34 |
Dividends per Share |